Indication:

GILMAT is indicated for the:,· treatment of patients with chronic myeloid leukaemia (CML),· treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,· treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,· treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed, · treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),
·treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
·adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials)
· treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).

Generic Name: Imatinib

Strength: 100mg

Dosage: Tabs

Shelflife Months: 36

Pack Size: 60

Tablet Description: White to off-white coloured, round, bevel edged scored tablets debossed with H on one side and 19 on the other side, 1 and 9 separated by a score line.

Segment :A

Innovator: Glivec®

PBSListed: Yes

RPBSlisted: No

Schedule: S4

Storage Conditions: Store below 25 degrees Celsius

Active Ingredients: imatinib mesilate 119.5mg
Equivalent: imatinib 100mg

Warnings: